Thomas Burrow, MD
Clinical Genetics (M.D.) · Little Rock, ARNPI 1699983155
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $102,632 of the $108,375 with a category attached, or 94.7%. 10 manufacturers reported payments, led by Modernatx, Inc. at 36.6% of the total. Reporting peaked in 2024 at $43,249 and has fallen 64.0% since, to $15,578 in 2025.
Across 67 payments — averaging $1617.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$40K
- Sanofi$38K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
- Sanofi-aventis U.S. LLC$9K
- Shire North American Group Inc$6K
- Sanofi US Services Inc.$2K
- plus $5K from 4 others
Across 207 payments — averaging $5754.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$462K
- Biomarin Pharmaceutical Inc.$292K
- Amicus Therapeutics, Inc.$238K
- Mallinckrodt Enterprises LLC$75K
- Mallinckrodt Hospital Products Inc.$50K
- Sanofi US Services Inc.$47K
- plus $27K from 2 others
What the payments were for
- Consulting fees$102,63295%
- Speaking & faculty fees$2,0752%
- Travel & lodging$2,7273%
- Food & beverage$9371%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 12 | $39,650 |
| Sanofi | 25 | $38,215 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $8,800 |
| Sanofi-aventis U.S. LLC | 14 | $8,767 |
| Shire North American Group Inc | 4 | $6,431 |
| Sanofi US Services Inc. | 4 | $2,000 |
| Bioverativ Therapeutics Inc. | 1 | $1,890 |
| Intrabio Inc | 1 | $1,575 |
| AstraZeneca | 1 | $1,025 |
| Eton Pharmaceuticals, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical genetics (m.d.) providers in Arkansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DojolviTriheptanoin | 12 | $299,054 |
| LevocarnitineLevocarnitine (With Sugar) | 11 | $3,308 |
| Metronidazole | 11 | $83 |
Paid to pharmacies, not to this prescriber.
Other clinical genetics (m.d.) in Little Rock
- Kelly JonesLittle Rock$561
- Adolfo GarnicaLittle Rock$20
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.